COVID-19 Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0RV9C
|
|||
| Drug Name |
GRL-001
|
|||
| Synonyms |
CE-5
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Middle East Respiratory Syndrome (MERS) | Preclinical | [1] | Severe acute respiratory syndrome (SARS) | Preclinical | [1] |
| Therapeutic Class |
Antiviral Agents
|
|||
| Structure |
 |
Download2D MOL |
||
| Target | Top | |||
|---|---|---|---|---|
| Target(s) | MERS-CoV 3C-like proteinase (3CLpro) | Target Info | Inhibitor | [1] |
| GRL-001, a 3CLpro inhibitor, demonstrates broad-spectrum in vitro activities against SARS-CoV and MERS-CoV with highly similar key residues for substrate recognition at their 3CLpro enzymes. | ||||
| SARS-CoV 3C-like protease (3CLpro) | Target Info | Inhibitor | [1] | |
| GRL-001, a 3CLpro inhibitor, demonstrates broad-spectrum in vitro activities against SARS-CoV and MERS-CoV with highly similar key residues for substrate recognition at their 3CLpro enzymes. | ||||
| References | Top | |||
|---|---|---|---|---|
| 1 | Coronaviruses - drug discovery and therapeutic options. Nat Rev Drug Discov. 2016 May;15(5):327-47. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.